GSK <\/b>“立足中國、攜手中國、服務中國”<\/b> <\/p> \n
我們一貫支持中國政府的醫療改革，致力于將質量更高、效果更好的創新產品帶給有需要的中國患者。 GSK 踐行“立足中國、攜手中國、服務中國”承諾的例證還包括：<\/p> \n
關于 <\/b>GSK<\/b>：<\/b><\/p> \n
GSK 是一家以科學為導向的全球醫藥保健公司，致力于讓人們能夠做到更多、感覺更舒適、生活更長久，從而提高人類的生活質量。更多信息請瀏覽 www.gsk.com<\/a>。<\/p> \n 參考文獻：<\/b><\/p> \n 1. Global initiative for chronic obstructive lung disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2018 report (2017) 圖片 - https:\/\/photos.prnasia.com\/prnh\/20180906\/2230091-1<\/a> <\/p>"];
$("#dvExtra").html(content_array[0]);})();
2. Tal-Singer R, Cahn A, Mehta R, et al<\/i>. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol, 2013, 701(1-3): 40-48.
3. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta 2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther, 2013, 26(2): 256-264.
4. Zhou Y, Zhong NS, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 2017 (9): 377: 923-935
5. Mu<\/span>llerova<\/span> H et al. PLoS One. 2014;9:e85540
6. Wang C. et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China<\/span> (the China Pulmonary Health [CPH] study): a national cross-sectional study (2018) The Lancet 2018: 391(10131)
7. Yi F., YI S. Epidemiological Investigation and Prevention Measures of Chronic Obstructive Pulmonary Disease. J Prev Med Chin PLA 2018 (2): Vol.36 No.2<\/p> \n